Silence Therapeutics (NASDAQ:SLN) Trading Down 3.5%

Silence Therapeutics plc (NASDAQ:SLN) fell 3.5% during mid-day trading on Tuesday . The stock traded as low as $18.09 and last traded at $18.09. 25,249 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 197,378 shares. The stock had previously closed at $18.74.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Chardan Capital upped their price objective on shares of Silence Therapeutics from $42.00 to $55.00 and gave the company a “buy” rating in a research report on Friday. HC Wainwright reissued a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a report on Thursday, June 27th. Finally, Morgan Stanley upped their target price on Silence Therapeutics from $45.00 to $49.00 and gave the company an “overweight” rating in a research note on Friday.

Silence Therapeutics Price Performance

The business’s 50 day simple moving average is $21.07 and its 200 day simple moving average is $21.05. The stock has a market cap of $539.04 million, a P/E ratio of -15.41 and a beta of 1.31.

Silence Therapeutics (NASDAQ:SLN) last posted its earnings results on Thursday, May 16th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.18. The business had revenue of $15.73 million during the quarter, compared to the consensus estimate of $4.53 million. Silence Therapeutics had a negative return on equity of 79.90% and a negative net margin of 131.44%. Research analysts predict that Silence Therapeutics plc will post -1.52 earnings per share for the current year.

Hedge Funds Weigh In On Silence Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC increased its stake in shares of Silence Therapeutics by 10.5% in the first quarter. SG Americas Securities LLC now owns 7,000 shares of the company’s stock valued at $151,000 after buying an additional 667 shares in the last quarter. Parkman Healthcare Partners LLC increased its position in Silence Therapeutics by 20.8% in the 4th quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock valued at $4,046,000 after acquiring an additional 40,063 shares in the last quarter. Lynx1 Capital Management LP raised its stake in shares of Silence Therapeutics by 123.4% in the first quarter. Lynx1 Capital Management LP now owns 526,642 shares of the company’s stock worth $11,375,000 after acquiring an additional 290,855 shares during the last quarter. Vivo Capital LLC bought a new position in shares of Silence Therapeutics in the fourth quarter worth about $8,862,000. Finally, Janus Henderson Group PLC acquired a new position in shares of Silence Therapeutics during the first quarter worth approximately $13,575,000. 98.73% of the stock is currently owned by institutional investors and hedge funds.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.